Literature DB >> 9973386

Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization.

R L Ferris1, C Hall, N V Sipsas, J T Safrit, A Trocha, R A Koup, R P Johnson, R F Siliciano.   

Abstract

Processing of viral proteins for recognition by CTL involves degradation of the proteins in the cytosol of an infected cell followed by transport of the resulting peptides into the endoplasmic reticulum (ER) by the TAP1/2 complex. Uncertainty exists over the site of processing of viral envelope (env) proteins since the extracellular domains of env proteins are not present in the cytosol where the class I Ag-processing pathway begins. Rather, the ectodomains of env proteins are cotranslationally translocated into the ER during biosynthesis. To analyze env protein processing, we used the herpes simplex virus protein ICP47 to block peptide transport by TAP1/2 and examined the effects of TAP blockade on the processing of the HIV-1 env protein. For the majority of env-specific CD8+ CTL, the processing pathway required TAP1/2-mediated transport of cytosolic peptides into the ER. To determine how env peptides are generated in the cytosol, we analyzed the processing of two TAP1/2-dependent epitopes containing N-linked glycosylation sites. In each case, processing involved glycosylation-dependent posttranslational modification of asparagine residues to aspartic acid. These results are consistent with cotranslational translocation of env into the ER, where glycosylation occurs. This is followed by export of a fraction of the newly synthesized protein into the cytosol, where it is deglycosylated, with conversion of the asparagines to aspartic acid residues. Following cytoplasmic proteolysis, env peptides are retransported by TAP1/2 into the ER, where association with class I occurs. Thus, the env protein can enter the class I pathway through multiple distinct processing mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973386

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.

Authors:  Shutao Mei; Rochelle Ayala; Sri H Ramarathinam; Patricia T Illing; Pouya Faridi; Jiangning Song; Anthony W Purcell; Nathan P Croft
Journal:  Mol Cell Proteomics       Date:  2020-05-01       Impact factor: 5.911

3.  The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.

Authors:  Victor H Engelhard
Journal:  Int J Mass Spectrom       Date:  2007-01-01       Impact factor: 1.986

4.  Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.

Authors:  Gabriela L Cosma; Jenna L Lobby; Elizabeth J Fay; Nicholas A Siciliano; Ryan A Langlois; Laurence C Eisenlohr
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

5.  An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Authors:  Alexandre Dalet; Paul F Robbins; Vincent Stroobant; Nathalie Vigneron; Yong F Li; Mona El-Gamil; Ken-ichi Hanada; James C Yang; Steven A Rosenberg; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

6.  Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.

Authors:  Pedro A Andrade Filho; Andrés López-Albaitero; William Gooding; Robert L Ferris
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

7.  Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes.

Authors:  Huabiao Chen; Alicja Piechocka-Trocha; Toshiyuki Miura; Mark A Brockman; Boris D Julg; Brett M Baker; Alissa C Rothchild; Brian L Block; Arne Schneidewind; Tomohiko Koibuchi; Florencia Pereyra; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

8.  A novel cytosolic class I antigen-processing pathway for endoplasmic-reticulum-targeted proteins.

Authors:  Eva Schlosser; Carolina Otero; Christine Wuensch; Benedikt Kessler; Mariola Edelmann; René Brunisholz; Ingo Drexler; Daniel F Legler; Marcus Groettrup
Journal:  EMBO Rep       Date:  2007-09-14       Impact factor: 8.807

9.  Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.

Authors:  G Lautscham; S Mayrhofer; G Taylor; T Haigh; A Leese; A Rickinson; N Blake
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

10.  Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas.

Authors:  Yanfei Xu; Sandra J Gendler; Alessandra Franco
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.